Philipp E. Hartrampf

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Kerstin Michalski, Juri Ruf, Christian Goetz et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 118 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

Prostate-specific Membrane Antigen Reporting and Data System Version 2.0

Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler et al. · European Urology · 2023 · 66 citations · Full text

Medicine, Oncology, Radiology +17

Long-Term Nephrotoxicity of¹⁷⁷Lu-PSMA Radioligand Therapy

Lisa Steinhelfer, Lukas Lunger, Lisena Cala et al. · Journal of Nuclear Medicine · 2023 · 64 citations · Full text

Medicine, Oncology, Urology +17

Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Philipp E. Hartrampf, Franz‐Xaver Weinzierl, Andreas K. Buck et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2022 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

Philipp E. Hartrampf, Heribert Hänscheid, Olivia Kertels et al. · Clinical and Translational Radiation Oncology · 2020 · 44 citations · Full text

Medicine, Nuclear Medicine, Oncology +17